hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06376422, orgStudyIdInfo id: EU-CT-2023-508271-36-00, briefTitle: Sterile Allogeneic Spongioflex® Allograft as Partial Meniscal Replacement After Incomplete Meniscal Loss, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2029-04-30, completionDateStruct date: 2031-04-30, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Privatpraxis für Knie- und Schulterchirurgie, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to learn if partial meniscal replacement can prevent or postpone total meniscal replacement, in adult patients (female/male) with partial meniscal loss. The main questions it aims to answer are:* Can partial meniscal replacement improve knee function?* Can partial meniscal replacement prevent/postpone total meniscal replacement/knee prothesis? Researchers will compare the results of the operated group with patients not willing to be operated but with partial meniscal loss to see if the operation improves knee function.Participants will be operated and have to attend follow-up visits with MRI after 6 months up to 5 years after surgery., conditionsModule conditions: Meniscus Lesion, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, maskingDescription: no masking, patient decides which group, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Spongioflex®, interventions name: non-operated, outcomesModule primaryOutcomes measure: To evaluate efficacy of the procedure, primaryOutcomes measure: Improvement of International Knee Documentation Committee (IKDC) score (between 0 and 100, the higher the better), primaryOutcomes measure: Improvement of Knee Injury and Osteoarthritis Outcome Score (KOOS) score (between 0 and 100, the higher the better), primaryOutcomes measure: Improvement of Visual Analogue Scale (VAS) Pain Score (between 0 and 10, the lower the better), secondaryOutcomes measure: Safety of the patient (adverse events (AE) and serious adverse events (SAE)), secondaryOutcomes measure: Efficacy of the procedure, progression to osteoarthrosis, secondaryOutcomes measure: Menuiscus size, secondaryOutcomes measure: extrusion of meniscus, secondaryOutcomes measure: Size of meniscal extrusion, secondaryOutcomes measure: Patient satisfaction, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Privatpraxis für Knie und Schulterchirurgie, status: RECRUITING, city: Dortmund, zip: 44137, country: Germany, contacts name: Sven Behrendt, MD, role: CONTACT, phone: +49231 8626064, email: praxis@dr-sven-behrendt.de, contacts name: Sven Behrendt, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 51.51494, lon: 7.466, hasResults: False
protocolSection identificationModule nctId: NCT06376396, orgStudyIdInfo id: 101103306, briefTitle: Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis, acronym: NeuroSolve, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06, primaryCompletionDateStruct date: 2025-12, completionDateStruct date: 2026-12, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-23, sponsorCollaboratorsModule leadSponsor name: R-Evolution Worldwide S.r.l. Impresa Sociale, class: OTHER, collaborators name: Muhimbili University of Health and Allied Sciences, collaborators name: National Institute for Medical Research, Tanzania, collaborators name: Sokoine University of Agriculture, collaborators name: University of Zambia, collaborators name: University Ghent, descriptionModule briefSummary: The goal of this clinical trial is to compare the combination albendazole and praziquantel versus albendazole alone in patients affected by neurocysticercosis., conditionsModule conditions: Neurocysticercosis, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule interventions name: albendazole and praziquantel, interventions name: Albendazole, outcomesModule primaryOutcomes measure: Cyst resolution or reduction in both study arms, secondaryOutcomes measure: Seizures frequency, secondaryOutcomes measure: Quality of Life questionnaire, secondaryOutcomes measure: Headache, secondaryOutcomes measure: Serological test results correlation with neuroimaging results, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06376383, orgStudyIdInfo id: TETT-RHG, secondaryIdInfos id: 110500, type: OTHER, domain: The Central Denmark Region Committees on Health Research Ethics, briefTitle: Tonsillectomy vs. Tonsillotomy in Adults With Obstructive Sleep Apnea, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2025-01, primaryCompletionDateStruct date: 2026-12, completionDateStruct date: 2027-09, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: University of Aarhus, class: OTHER, descriptionModule briefSummary: The primary purpose of this randomized controlled trial s to investigate whether surgical reduction of palatine tonsils (tonsillotomy) is a superior treatment compared to complete surgical removal of palatine tonsils (tonsillectomy) in adults patients with obstructive sleep apnea and concomitant enlarged tonsils in regards of perioperative and postoperative morbidity., conditionsModule conditions: Obstructive Sleep Apnea, conditions: Tonsillar Hypertrophy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 464, type: ESTIMATED, armsInterventionsModule interventions name: Tonsillectomy, interventions name: Tonsillotomy, outcomesModule primaryOutcomes measure: Postoperative hemorrhage, primaryOutcomes measure: Postoperative pain, primaryOutcomes measure: Recovery time - Sick leave, primaryOutcomes measure: Morbidity, secondaryOutcomes measure: AHI, secondaryOutcomes measure: DISE - VOTE, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06376370, orgStudyIdInfo id: 16.04.24/2, briefTitle: The Effect of a Computer-Assisted Rehabilitation Program on Epilepsy Patient, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-04-26, primaryCompletionDateStruct date: 2024-06-10, completionDateStruct date: 2024-07-28, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Selcuk University, class: OTHER, descriptionModule briefSummary: The aim of this study is to examine the effects of the RehaCom Computer-Assisted Rehabilitation Program Applied to Epilepsy Patients on Self-Management, Cognitive Function and Quality of Life., conditionsModule conditions: Epilepsy, conditions: Computer-assisted Cognitive Rehabilitation, conditions: Quality of Life, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: SINGLE, whoMasked: INVESTIGATOR, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Application of computer-assisted cognitive rehabilitation program, outcomesModule primaryOutcomes measure: Mini Mental State Test, primaryOutcomes measure: Epilepsy Quality of Life Scale, primaryOutcomes measure: MOXO Test, primaryOutcomes measure: Epilepsy Self-Management Scale, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: ülkü Saygili Düzova, city: Selçuklu, state: Konya, country: Turkey, geoPoint lat: 37.8842, lon: 32.49222, hasResults: False
protocolSection identificationModule nctId: NCT06376357, orgStudyIdInfo id: 16.04.24/1, briefTitle: The Effect of Foot Massage With Roles on Cancer Patients, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-04-27, primaryCompletionDateStruct date: 2024-06-15, completionDateStruct date: 2024-07-30, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Selcuk University, class: OTHER, descriptionModule briefSummary: It was aimed to examine the roles in the management of treatment-related peripheral neuropathy in cancer patients receiving taxane-based chemotherapy and the effect of foot massage on neuropathy and quality of life., conditionsModule conditions: Breast Neoplasms, conditions: Over Cancer, conditions: Foot Massage, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: SINGLE, whoMasked: INVESTIGATOR, enrollmentInfo count: 54, type: ESTIMATED, armsInterventionsModule interventions name: Foot Massage with roller, outcomesModule primaryOutcomes measure: EORTC QLQ C-30 Quality of Life Scale, primaryOutcomes measure: CIPN20 Neuropathy Scale, primaryOutcomes measure: One Leg Standing Test, primaryOutcomes measure: Brief Pain Inventory BPI, primaryOutcomes measure: Pain Threshold Assessment Test, primaryOutcomes measure: Two Point Discrimination, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: ülkü Saygili Düzova, city: Selçuklu, state: Konya, country: Turkey, geoPoint lat: 37.8842, lon: 32.49222, hasResults: False
protocolSection identificationModule nctId: NCT06376344, orgStudyIdInfo id: 16.04.24, briefTitle: The Effect of Tennis Ball on Balance and Quality of Life in Cancer Patients With Neuropathy., statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-04-28, primaryCompletionDateStruct date: 2024-06-10, completionDateStruct date: 2024-07-10, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Selcuk University, class: OTHER, descriptionModule briefSummary: This research; It was aimed to evaluate the effect of myofascial release using a tennis ball on balance and quality of life in cancer patients who developed peripheral neuropathy., conditionsModule conditions: Cancer, conditions: Neuropathy, conditions: Therapy-Associated Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: SINGLE, whoMasked: INVESTIGATOR, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: myofascial release with tennis ball, outcomesModule primaryOutcomes measure: EORTC QLQ C-30- CIPN20 Scale, primaryOutcomes measure: One Leg Standing Test, primaryOutcomes measure: Lateral Reach Test, primaryOutcomes measure: Pain Assessment, primaryOutcomes measure: Pressure Pain Threshold Assessment, primaryOutcomes measure: Two Point Discrimination, eligibilityModule sex: ALL, minimumAge: 25 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: ülkü Saygili Düzova, city: Selçuklu, state: Konya, country: Turkey, geoPoint lat: 37.8842, lon: 32.49222, hasResults: False
protocolSection identificationModule nctId: NCT06376331, orgStudyIdInfo id: ADHD20240403, briefTitle: Washed Microbiota Transplantation for Attention-deficit/Hyperactivity Disorder, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-20, primaryCompletionDateStruct date: 2027-06-01, completionDateStruct date: 2027-07-01, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: The Second Hospital of Nanjing Medical University, class: OTHER, collaborators name: SIR RUN RUN hospital of Nanjing Medical University, descriptionModule briefSummary: Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder characterized by inattention and hyperactivity-impulsivity. ADHD is often accompanied by oppositional defiant disorder and sleep disturbance, and can increase the risk of other psychiatric disorders, functional impairment in academic and occupational performance. Recently, gut microbiota has been implicated in the ADHD via gut-brain axis. In this study, investigators aimed to evaluate the efficacy of WMT for core ADHD symptoms and its comorbidities using specialized questionnaires for ADHD and investigate the underlying mechanism., conditionsModule conditions: Attention-deficit/Hyperactivity Disorder, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: washed microbiota transplantation, outcomesModule primaryOutcomes measure: change of Swanson, Nolan and Pelham-IV (SNAP-IV)., primaryOutcomes measure: change of Chinese version of the Conners abbreviated symptom questionnaire (C-ASQ)., secondaryOutcomes measure: change of the Sleep Disturbance Scale for Children (SDSC)., secondaryOutcomes measure: change of the Gastrointestinal Symptom Rating Scale (GSRS) ., secondaryOutcomes measure: the difference of the gut microbe composition between children with ADHD and healthy children by sequencing faecal metagenome., secondaryOutcomes measure: the difference of the serum neurotransmitters between children with ADHD and healthy children, secondaryOutcomes measure: intestinal barrier, eligibilityModule sex: ALL, minimumAge: 6 Years, maximumAge: 17 Years, stdAges: CHILD, contactsLocationsModule locations facility: Department of Microbiota Medicine & Medical Centre for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University, city: Nanjing, state: Jiangsu, country: China, contacts name: Faming Zhang, PhD, role: CONTACT, phone: 086-025-58509883, email: fzhang@njmu.edu.cn, geoPoint lat: 32.06167, lon: 118.77778, locations facility: SIR RUN RUN hospital of Nanjing Medical University, city: Nanjing, state: Jiangsu, country: China, geoPoint lat: 32.06167, lon: 118.77778, hasResults: False
protocolSection identificationModule nctId: NCT06376318, orgStudyIdInfo id: 19-138, briefTitle: Shock and Acute Conditions OutcOmes Platform, acronym: ShockCO-OP, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-01-01, primaryCompletionDateStruct date: 2025-07-01, completionDateStruct date: 2026-01-01, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Saint-Louis Hospital, Paris, France, class: OTHER, collaborators name: University of Helsinki, collaborators name: University of Ottawa, collaborators name: University of Leipzig, collaborators name: University of Nancy, collaborators name: McGill University, collaborators name: Mayo Clinic, collaborators name: University of Paris 5 - Rene Descartes, collaborators name: University of Toronto, descriptionModule briefSummary: In-hospital mortality of patients admitted in the intensive care unit (ICU) for circulatory shock remains high (between 20 and 40%).Currently, there are no markers that allow us to classify patients with circulatory shock at higher risk of early and late bad outcomes, or who may better respond to a specific intervention.To understand the contribution of biological heterogeneity to circulatory shock independently from its etiology, the ShockCO-OP Research Program aims to use clustering approaches to re-analyze existing clinical and molecular data from several large European and North American prospective cohorts and clinical trials.This will enable an improvement in risk prediction and a better patient selection in future clinical trials to assess a personalized therapy (i.e., prospective enrollment based on a biological/molecular signature)., conditionsModule conditions: Circulatory Shock, conditions: Sepsis, conditions: Cardiogenic Shock, conditions: Major Trauma, conditions: Surgical Shock, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: OTHER, enrollmentInfo count: 1000, type: ESTIMATED, armsInterventionsModule interventions name: Inotrope, interventions name: Mechanical circulatory support, interventions name: anti-bodies, outcomesModule primaryOutcomes measure: Mortality rate, secondaryOutcomes measure: Mortality rate, secondaryOutcomes measure: Renal replacement therapy use rate, secondaryOutcomes measure: Mechanical circulatory support use rate, secondaryOutcomes measure: Vasopressors and inotropes-free days, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: St Michael's Hospital, city: Toronto, state: Ontario, zip: M5B 1W8, country: Canada, geoPoint lat: 43.70011, lon: -79.4163, hasResults: False
protocolSection identificationModule nctId: NCT06376292, orgStudyIdInfo id: Y⒛24-0106, briefTitle: A Prospective Study of Whole-Brain RT Combined With Thiotepa Sheath Injection Combined With Systemic Therapy for the Primary Disease in the Treatment of Meningeal Metastases in Solid Tumors, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-01, primaryCompletionDateStruct date: 2026-02-01, completionDateStruct date: 2026-02-01, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Second Affiliated Hospital, School of Medicine, Zhejiang University, class: OTHER, descriptionModule briefSummary: The goal of this prospective, single-arm exploratory clinical study is to explore the safty and efficacy of whole-brain radiotherapy combined with Thiotepa sheath injection combined With Systemic Therapy for the Primary Disease in the Treatment of Meningeal Metastases in Solid TumorsHow works well was the combined therapy？ How safe was combined therapy？ Participants will receive whole brain radiotherapy combined with intrathecal injection of Thiotepa twice a week for a total of 4 weeks. Evaluate the efficacy and safety every 2 cycles.Researchers will evaluate whether this combination treatment is safe and whether it is more effective than previous studies., conditionsModule conditions: Solid Tumor Leptomeningeal Metastasis, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Participants will receive a comprehensive treatment plan consisting mainly of whole brain 30Gy/10F radiotherapy combined with intrathecal injection of Thiotepa twice a week for a total of 4 weeks., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Intrathecal Injection of Thiotepa+Radiation+Systemic Treatment of Primary Diseases, outcomesModule primaryOutcomes measure: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability], secondaryOutcomes measure: OS, secondaryOutcomes measure: 3-month PFS, secondaryOutcomes measure: 6-month PFS, secondaryOutcomes measure: 1-year PFS, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The Second Affiliated Hospital of Zhejiang University, status: RECRUITING, city: Hangzhou, state: Zhejiang, zip: 310000, country: China, contacts name: Ting Zhang, Prof., role: CONTACT, phone: +8615157125533, email: zezht@zju.edu.cn, geoPoint lat: 30.29365, lon: 120.16142, documentSection largeDocumentModule largeDocs typeAbbrev: Prot, hasProtocol: True, hasSap: False, hasIcf: False, label: Study Protocol, date: 2024-03-12, uploadDate: 2024-03-13T09:04, filename: Prot_000.pdf, size: 320618, largeDocs typeAbbrev: ICF, hasProtocol: False, hasSap: False, hasIcf: True, label: Informed Consent Form, date: 2024-03-12, uploadDate: 2024-03-13T09:05, filename: ICF_001.pdf, size: 156721, hasResults: False
protocolSection identificationModule nctId: NCT06376279, orgStudyIdInfo id: 2008/351-31, briefTitle: Genetic Diagnosis in Inborn Errors of Metabolism, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2008-04-29, primaryCompletionDateStruct date: 2030-12-31, completionDateStruct date: 2030-12-31, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Region Stockholm, class: OTHER_GOV, collaborators name: Karolinska Institutet, descriptionModule briefSummary: Inborn Errors of metabolism comprise a large number of rare conditions with a collective incidence of around 1/2000 newborns. Many disorders are treatable provided that a correct diagnosis can be established in time, and for many diseases novel therapies are being developed. Without treatment, many of the conditions result in early death or severe irreversible handicaps.The Centre for Inherited Metabolic Diseases, CMMS at Karolinska university hospital, is an integrated expert center where clinical specialists work closely together with experts in laboratory medicine, combining clinical genetics, clinical chemistry, pediatrics, neurology, and endocrinology. The center serves the whole Swedish population with diagnostics and expert advice on IEM and has a broad arsenal of biochemical investigations designed to detect defects in intermediary metabolism., conditionsModule conditions: Metabolic Disease, conditions: Mitochondrial Diseases, conditions: Epilepsy in Children, conditions: Epilepsy, conditions: LHON, conditions: Motor Neuron Disease, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 1000, type: ESTIMATED, armsInterventionsModule interventions name: IEM-EP, outcomesModule primaryOutcomes measure: Genetic variant identification using NGS for diagnosis, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False